Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-20
DOI
10.1038/s41388-019-1102-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
- (2019) Amy S. Clark et al. CLINICAL CANCER RESEARCH
- Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
- (2019) Joan Cao et al. ONCOGENE
- Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
- (2019) Erik S. Knudsen et al. ONCOGENE
- CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
- (2018) Mangala Iyengar et al. Oncotarget
- Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
- (2018) Agnieszka K. Witkiewicz et al. Cell Reports
- Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
- (2018) Eric Haines et al. Oncotarget
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
- (2017) Erik S Knudsen et al. GUT
- CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest
- (2017) Ashleigh M. Francis et al. MOLECULAR CANCER THERAPEUTICS
- Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
- (2017) Shenghui He et al. Science Translational Medicine
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
- (2016) Erik S. Knudsen et al. GASTROENTEROLOGY
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Management of Metastatic Pancreatic Adenocarcinoma
- (2016) Ahmad R. Cheema et al. SURGICAL CLINICS OF NORTH AMERICA
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
- (2015) Manuel Hidalgo et al. PANCREATOLOGY
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
- (2015) Agnieszka K. Witkiewicz et al. Oncotarget
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- (2015) Barbie Taylor-Harding et al. Oncotarget
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Genetic Progression of Pancreatic Cancer
- (2014) Robert W. Cowan et al. CANCER JOURNAL
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of G2/M phase cell cycle arrest and apoptosis by ginsenoside Rf in human osteosarcoma MG-63 cells through the mitochondrial pathway
- (2013) WEN-JI SHANGGUAN et al. ONCOLOGY REPORTS
- Signaling Pathways that Control Cell Proliferation
- (2013) R. J. Duronio et al. Cold Spring Harbor Perspectives in Biology
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
- (2012) A. Kathleen McClendon et al. CELL CYCLE
- Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
- (2012) Jeffry L. Dean et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DNA damage-dependent cyclin D1 proteolysis: GSK3β holds the smoking gun
- (2011) Laura L. Pontano et al. CELL CYCLE
- Persistent p21 Expression after Nutlin-3a Removal Is Associated with Senescence-like Arrest in 4N Cells
- (2010) Hong Shen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
- (2010) Søren M. Johnson et al. JOURNAL OF CLINICAL INVESTIGATION
- Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway
- (2008) E E Hoskins et al. ONCOGENE
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started